Close

GSK-Novartis healthcare venture to lay off 350 in Parsippany, New Jersey

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...
The joint venture of GlaxoSmithKline's and Novartis's consumer health-care businesses will result in the cutting of 350 jobs in New Jersey, with reductions coming from each of the companies' Parsippany locations, a GlaxoSmithKline representative said Wednesday.
The job cuts that began last month, will continue through the rest of this year, said MalesiaDunn, a GlaxoSmithKline spokeswoman. "We are looking at bringing together the very best talent from both organizations," she said.
The reason for the layoffs, disclosed Tuesday in a notice filed with the New Jersey Department of Labor & Workforce Development, is "to meet established financial and synergy targets and eliminate duplication," GlaxoSmithKline said in the so-called WARN notice.
Employees being laid off include marketing and medical affairs managers and associates, sales and operations associates, finance personnel, information technology personnel, consumer relations managers and associates, and regulatory affairs managers and associates.
Severance pay and job placement services will be available, said Dunn. She could not immediately provide details on those programs, nor did she know how many employees will remain next year when the joint-venture partners move into one new Parsippany location, which has not yet been identified.
In the meantime, the GlaxoSmithKline employees will continue to work at 1500 Littleton Road and the Novartis employees will continue to work at 200 Kimball Drive, she said.
The previously announced deal will result in Novartis owning a 36.5 percent share of the venture and filling four of 11 seats on venture's board.
The joint venture offers wellness, oral health,nutrition and skin products.

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back